Indrayani Biotech

Indrayani Biotech said on July 15 that the Income Tax Appellate Tribunal has quashed an earlier appellate order relating to a ₹13.90 crore tax demand and restored the matter to the First Appellate Authority for fresh adjudication. The company had challenged the assessment order for assessment year 2023-24, first before the First Appellate Authority and then before the tribunal. The ruling removes the immediate threat of a tax liability that was equivalent to about 22% of Indrayani Biotech's market capitalisation.

Powered by Tijori

Indrayani Biotech has indefinitely postponed its ₹49.90 crore partly paid-up rights issue, the company said on June 22, after previously extending the schedule twice. The Rights Issue Committee decided to halt the process until further notice, while retaining the same offer price and entitlement ratio announced earlier. The capital raise, first disclosed in April 2026, was intended to shore up the company's balance sheet as it navigates financial distress and an NPA classification. The issue size is roughly 60% of Indrayani Biotech's current market capitalisation of ₹83 crores, making it a pivotal event for the company's survival. A revised timeline will be communicated separately once the committee finalises a new schedule.

Powered by Tijori

April 9 (Reuters) - Indrayani Biotech Ltd INBT.BO:

• BOARD DISCUSSES PRELIMINARY DEMERGER PROPOSAL FOR FOOD DIVISION

Source text: ID:nBSE73bDQh

Further company coverage: INBT.BO

(([email protected];;))

April 3 (Reuters) - Indrayani Biotech Ltd INBT.BO:

• CFO VINAYAKA BODALA RESIGNS

• APPOINTS DHINAKARAN RAJAGOPAL AS CFO

Source text: ID:nBSE5SG3lj

Further company coverage: INBT.BO

(([email protected];;))

Nov 11 (Reuters) - Indrayani Biotech Ltd INBT.BO:

• INDRAYANI BIOTECH LTD - TO CONSIDER ISSUE OF SHARES VIA RIGHTS ISSUE

Source text: ID:nBSE7jR0yd

Further company coverage: INBT.BO

(([email protected];))

Aug 29 (Reuters) - Indrayani Biotech Ltd INBT.BO:

• IBL HEALTHCARE DISINVESTED 52,970 EQUITY SHARES OF IHHC

• CONSIDERATION RECEIVED FROM SALE 5.3 MILLION RUPEES

Source text for Eikon: ID:nBSE9YG82v

Further company coverage: INBT.BO

(([email protected];))

Aug 25 (Reuters) - Indrayani Biotech Ltd INBT.BO:

• UNIT IBL HEALTHCARE INVESTED IN KNISS LABORATORIES BY SUBSCRIBING TO EQUITY SHARES OF CO

• COST OF ACQUISITION 54.7 MILLION RUPEES

Source text for Eikon: ID:nBSEb4sN15

Further company coverage: INBT.BO

(([email protected];))

July 13 (Reuters) - Indrayani Biotech Ltd INBT.BO:

• UNIT INTENDS TO ACQUIRE CONTROLLING STAKES IN M/S PEEKAY MEDIEQUIP

• COST OF ACQUISITION AT 55.4 MILLION RUPEES AS FIRST TRANCHE

Source text for Eikon: ID:nBSE1ytKTJ

Further company coverage: INBT.BO

(([email protected];;))